Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1

Interventions

Metformin 3Letrozole 3Sperm Injections, Intracytoplasmic 2Progesterone 2Lidocaine 2Indocyanine Green 2Gentamicins 2Estradiol 2Clomiphene 2Bevacizumab 2Acitretin 2tirbanibulin 1technetium Tc 99m nanocolloid 1suvorexant 1pomalidomide 1pembrolizumab 1pasireotide 1nilotinib 1methylnaltrexone 1ledipasvir 1ixazomib 1gadolinium ethoxybenzyl DTPA 1gadofosveset trisodium 1exemestane 1encorafenib 1dolutegravir 1ceftolozane, tazobactam drug combination 1binimetinib 1bicalutamide 1apatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Withdrawn × Lidocaine, Prilocaine Drug Combination × Clear all
NCT06023368 2024-11-14

Reducing Port Access Pain and Clinic Wait Time: An Evaluation of EMLA Cream Versus nüm™ Vapocoolant Spray

University of Kentucky

Phase 4 Withdrawn
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡